The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly.
作者： P.G. Van Buynder , S. Konrad , J.L. Van Buynder , E. Brodkin , M. Krajden
DOI: 10.1016/J.VACCINE.2013.07.059
关键词:
摘要: Abstract Background Influenza is associated with a high mortality and morbidity in older adults. Vaccination remains the most effective method of preventing influenza its consequences, however, vaccine effectiveness decreases increasing age immunosenescence. In adults, immunogenicity studies suggest an MF59 adjuvanted (ATIV, Fluad ® ) may help. Methods We evaluated comparative ATIV, unadjuvanted trivalent (TIV) reducing laboratory confirmed elderly. Elderly three health authorities during winter 2011–12 were included community based case control study design. Cases tested positive controls negative for influenza. Subjects known immunosuppression excluded. Logistic regression was used to calculate odds ratio vaccination (vs. no vaccination) cases controls. ATIV TIV described. Results A total 282 eligible participants enrolled (84 cases). Almost half (136) long term care facility 85 years or (132) decreased age. variety multivariate analyses, significantly protective at around 60% ( p = 0.02), only residence authority also significant. Vaccine increased non-long residents. analyses ineffective. Conclusion An provided improved protection against
core.ac.uk
sci-hub.se 参考文章(22)
Suryaprakash Sambhara, Janet E. McElhaney, Immunosenescence and Influenza Vaccine Efficacy Current Topics in Microbiology and Immunology. ,vol. 333, pp. 413- 429 ,(2009) , 10.1007/978-3-540-92165-3_20
Anthony E. Fiore, Carolyn B. Bridges, Nancy J. Cox, Seasonal Influenza Vaccines Current Topics in Microbiology and Immunology. ,vol. 333, pp. 43- 82 ,(2009) , 10.1007/978-3-540-92165-3_3
Various, Canadian Consensus Conference on Influenza Canadian Journal of Infectious Diseases & Medical Microbiology. ,vol. 4, pp. 251- 256 ,(1993)
P. G. Van Buynder, J. K. Dhaliwal, J. L. Van Buynder, C. Couturier, M. Minville-LeBlanc, R. Garceau, F.-W. Tremblay, Protective effect of single-dose adjuvanted pandemic influenza vaccine in children. Influenza and Other Respiratory Viruses. ,vol. 4, pp. 171- 178 ,(2010) , 10.1111/J.1750-2659.2010.00146.X
Paolo Durando, Giancarlo Icardi, Filippo Ansaldi, MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk Expert Opinion on Biological Therapy. ,vol. 10, pp. 639- 651 ,(2010) , 10.1517/14712591003724662
Eelko Hak, Feifei Wei, James Nordin, John Mullooly, Sung Poblete, Kristin L. Nichol, Development and Validation of a Clinical Prediction Rule for Hospitalization Due to Pneumonia or Influenza or Death during Influenza Epidemics among Community-Dwelling Elderly Persons The Journal of Infectious Diseases. ,vol. 189, pp. 450- 458 ,(2004) , 10.1086/381165
W.E.P. Beyer, J.J.P. Nauta, A.M. Palache, K.M. Giezeman, A.D.M.E. Osterhaus, Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis. Vaccine. ,vol. 29, pp. 5785- 5792 ,(2011) , 10.1016/J.VACCINE.2011.05.040
Y. Chen, D. Cui, S. Zheng, S. Yang, J. Tong, D. Yang, J. Fan, J. Zhang, B. Lou, X. Li, X. Zhuge, B. Ye, B. Chen, W. Mao, Y. Tan, G. Xu, Z. Chen, N. Chen, L. Li, Simultaneous Detection of Influenza A, Influenza B, and Respiratory Syncytial Viruses and Subtyping of Influenza A H3N2 Virus and H1N1 (2009) Virus by Multiplex Real-Time PCR Journal of Clinical Microbiology. ,vol. 49, pp. 1653- 1656 ,(2011) , 10.1128/JCM.02184-10
Th ME Govaert, CTMCN Thijs, Nic Masurel, MJW Sprenger, GJ Dinant, JA Knottnerus, None, The Efficacy of Influenza Vaccination in Elderly Individuals: A Randomized Double-blind Placebo-Controlled Trial JAMA. ,vol. 272, pp. 1661- 1665 ,(1994) , 10.1001/JAMA.1994.03520210045030
Isabel Leroux-Roels, Roger Bernhard, Pascal Gérard, Mamadou Dramé, Emmanuel Hanon, Geert Leroux-Roels, Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine PLoS ONE. ,vol. 3, pp. e1665- ,(2008) , 10.1371/JOURNAL.PONE.0001665